Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine

SHANGHAI, CHINA, May 13, 2022 – (ACN Newswire via – Hua Medicine (the “Company”, stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces … Read More